Recruiting INTERVENTIONAL NCT06875310

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Sponsor: Mirati Therapeutics Inc.

Conditions Carcinoma, Non-Small-Cell Lung

Interventions Adagrasib Carboplatin Cisplatin Pembrolizumab Pemetrexed Placebo

Updated 13 times since 2025 Last updated: Apr 24, 2026 Started: Apr 24, 2025 Primary completion: Sep 7, 2029 Completion: Apr 30, 2032

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Carcinoma, Non-Small-Cell Lung and is currently actively recruiting participants. Mirati Therapeutics Inc. leads this study, which shows 13 recorded versions since 2025 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

13 versions recorded

Apr 28, 2026 — Present [daily]

Recruiting

Phase: PHASE3 → None
Mar 2026 — Apr 2026 [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3

▶ Show 8 earlier versions

Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Apr 2025 — May 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Contact Information

Sponsor contact:

Mirati Therapeutics Inc.

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , ABB, Argentina , Adana, Turkey (Türkiye) , Ahmedabad, India , Ahmedabad, India , Akashi, Japan , Amiens, France , Amsterdam, Netherlands , Angers, France , Ankara, Turkey (Türkiye) and 341 more locations